RxDoctor Payments Data

Florin Stuleanu, MD

Pulmonary Disease · Cudahy, WINPI 1316958705

Payments from drug & device makers

$584in general payments, 2019–2025

Across 27 payments — averaging $21.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mylan Specialty L.p.$94
  • Jazz Pharmaceuticals Inc.$87
  • AstraZeneca$82
  • Regeneron Healthcare Solutions, Inc.$75
  • Baxter Healthcare$54
  • GSK$36
  • plus $155 from 9 others

What the payments were for

  • Food & beverage$50887%
  • Education$7513%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$584 in reported general payments places this provider in the 45th percentile of 247 pulmonary disease providers in Wisconsin.

See all pulmonary disease providers in Wisconsin

Medicare billing

Part B allowed, 2024
$94,372
Medicare patients
387
Services billed
1,204

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter428$417,047
Breo ElliptaFluticasone/Vilanterol112$61,401
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr48$36,738
SymbicortBudesonide/Formoterol Fumarate102$26,911
Spiriva RespimatTiotropium Bromide36$24,789
Spiriva HandihalerTiotropium Bromide22$17,718
Combivent RespimatIpratropium/Albuterol Sulfate18$17,489
Breztri AerosphereBudesonide/Glycopyr/Formoterol22$17,357
Albuterol Sulfate HfaAlbuterol Sulfate348$11,991
Stiolto RespimatTiotropium Br/Olodaterol Hcl19$10,673
Fluticasone-SalmeterolFluticasone Propion/Salmeterol49$7,776
Advair HfaFluticasone Propion/Salmeterol20$7,736
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate16$6,710
Wixela InhubFluticasone Propion/Salmeterol46$6,154
Incruse ElliptaUmeclidinium Bromide16$5,760

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$36$523,971615 claims
Boehringer IngelheimSpiriva Respimat, Combivent Respimat, Stiolto Respimat$16$52,95073 claims
AstraZenecaSymbicort, Breztri Aerosphere$82$44,269124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 247 pulmonary disease providers in Wisconsin.

Other pulmonary disease in Cudahy

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →